Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

>

>|

Found 5 Matches

Emtricitabine

Brand Name(s) include: Emtriva, Truvada

Disease: HIV

Drug Class: Nucleoside reverse transcriptase inhibitor

Date of Review: 2020

Number of Models Reviewed: 2

Number of Models added to the Repository: 2

The models at-a-glance

 

Version 13

 Publication

De Sousa Mendes, M., Hirt, D., Urien, S., Valade, E., Bouazza, N., Foissac, F., Blanche, S., Treluyer, J. M., & Benaboud, S. (2015). Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. British journal of clinical pharmacology, 80(5), 1031–1041.

 Simcyp Version

V13

 Published Model Application

Prediction of exposure in pregnancy

 Absorption Model

First Order

 Volume of Distribution Details

Full PBPK

 Route of Elimination

  • Renal Elimination
  • Includes uptake by OCT2 and efflux by MRP4 in the kidney

 Perpetrator DDI

  • None 

 Advantages and Limitations

  • Model developed in healthy volunteers and verified in pregnant women.
  • Renal transporters not verified with clinical data

 Model Compound Files

  • v13_res_emtricitabine_simcyp_mendex2015

 

 

 

 

 

 

Version 17

 Publication

De Sousa Mendes M, Chetty M. Are Standard Doses of Renally-Excreted  Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Drugs R D. 2019 Dec;19(4):339-350.

 Simcyp Version

 V17

 Published Model Application

 Prediction of exposure in renal impairment

 Absorption Model

First Order

 Volume of Distribution Details

Full PBPK

 Route of Elimination

  • Renal Elimination
  • Additional non-specific clearance

 Perpetrator DDI

  • None 

 Advantages and Limitations

  • Model developed to extrapolate elderly populations and renally impaired populations.
  • Model was verified in the elderly and young population

 Model Compound Files

  • v17_res_emtricitabine_simcyp_mendex2019.cmpz

 

 

|<

<

1

2

>

>|